Compare Honeywell International Inc (HON) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Invesco Ltd. — how do they compare? Honeywell International Inc trades at $229.58 (market cap $71.66B), while Invesco Ltd. trades at $29.68 (market cap $13.15B). The key difference: Honeywell International Inc is far larger — about 5.4× Invesco Ltd.'s market cap, and Honeywell International Inc pays the higher dividend (4.21%). Which is the better fit depends on your goals.
| HON | IVZ | |
|---|---|---|
Market Cap | $71.66B | $13.15B |
Sector | Industrials | Financials |
52-Week High | $248.04 | $30.30 |
52-Week Low | $188.14 | $20.20 |
Enterprise Value | $96.01B | $23.39B |
Dividend Yield | 4.21% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $229.86, up 2.15% with a bullish technical signal and strong analyst support. The company maintains solid profitability with 10.89% net margin and 26.41% ROE, though recent earnings show some pressure with Q2 2026 expectations at $1.80 EPS. Recent developments include a completed 2:1 reverse stock split and the acquisition of Johnson Matthey's Catalyst Technologies business for £1.325 billion, positioning the company for growth in automation and industrial technology.
HON presents a compelling investment case with 65% analyst buy ratings and a $368.55 consensus price target representing 60% upside. However, risks include declining profit margins (12.63% in 2025 vs 14.81% in 2024), increasing debt-to-asset ratio (46.65% in 2025), and near-term earnings uncertainty post-spinoffs. The stock's valuation at 18.07 P/E appears reasonable given its market leadership and strategic repositioning.
Invesco (IVZ) trades at $30.10, up 1.59% with a bullish technical outlook supported by moving averages. The company reported mixed Q1 2026 earnings, missing estimates after two consecutive beats. While revenue has grown to $6.38 billion in 2025, net income remains negative at -$281.7 million, though improving from 2023 lows. Analyst consensus shows 42.9% buy ratings with a $30.64 price target, slightly above current levels.
IVZ presents a balanced risk-reward profile with improving operational cash flow ($1.53B in 2025) and positive earnings momentum offset by persistent negative profitability metrics. The stock's valuation appears reasonable with P/E of 19.48 and P/B of 1.35, but investors face execution risks amid competitive asset management pressures and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
